Artios Unveils Promising Phase 1/2a Data for Polθ Inhibitor ART6043 at ESMO 2025

Reuters10-20

Artios Unveils Promising Phase 1/2a Data for Polθ Inhibitor ART6043 at ESMO 2025

IP Group plc announced new clinical data from Artios Pharma Limited regarding its novel DNA polymerase Theta (Polθ) inhibitor, ART6043. The results from the Phase 1/2a clinical study (NCT05898399) were presented at the European Society for Medical Oncology (ESMO) Congress 2025. The study evaluated ART6043 both as a monotherapy and in combination with the PARP inhibitor olaparib in patients with advanced solid tumors, particularly those with mutations in DNA damage response pathways. ART6043 demonstrated an attractive tolerability profile, expected pharmacokinetic and pharmacodynamic activity, and promising clinical signals. The findings support the potential advancement of ART6043 into Phase 2 clinical development. Full abstracts will be published in the ESMO Congress 2025 Abstract Book, a supplement to the Annals of Oncology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2576882113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 13:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576882113","market":"nz","top_or_hot":-1,"title":"Artios Unveils Promising Phase 1/2a Data for Polθ Inhibitor ART6043 at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Artios Unveils Promising Phase 1/2a Data for Polθ Inhibitor ART6043 at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IP Group plc announced new clinical data from Artios Pharma Limited regarding its novel DNA polymerase Theta (Polθ) inhibitor, ART6043. The results from the Phase 1/2a clinical study (NCT05898399) were presented at the European Society for Medical Oncology (ESMO) Congress 2025. The study evaluated ART6043 both as a monotherapy and in combination with the PARP inhibitor olaparib in patients with advanced solid tumors, particularly those with mutations in DNA damage response pathways. ART6043 demonstrated an attractive tolerability profile, expected pharmacokinetic and pharmacodynamic activity, and promising clinical signals. The findings support the potential advancement of ART6043 into Phase 2 clinical development. Full abstracts will be published in the ESMO Congress 2025 Abstract Book, a supplement to the Annals of Oncology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artios Unveils Promising Phase 1/2a Data for Polθ Inhibitor ART6043 at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtios Unveils Promising Phase 1/2a Data for Polθ Inhibitor ART6043 at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 13:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Artios Unveils Promising Phase 1/2a Data for Polθ Inhibitor ART6043 at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IP Group plc announced new clinical data from Artios Pharma Limited regarding its novel DNA polymerase Theta (Polθ) inhibitor, ART6043. The results from the Phase 1/2a clinical study (NCT05898399) were presented at the European Society for Medical Oncology (ESMO) Congress 2025. The study evaluated ART6043 both as a monotherapy and in combination with the PARP inhibitor olaparib in patients with advanced solid tumors, particularly those with mutations in DNA damage response pathways. ART6043 demonstrated an attractive tolerability profile, expected pharmacokinetic and pharmacodynamic activity, and promising clinical signals. The findings support the potential advancement of ART6043 into Phase 2 clinical development. Full abstracts will be published in the ESMO Congress 2025 Abstract Book, a supplement to the Annals of Oncology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPO.UK","symbol_name":"IP GROUP","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL5hWxPD:1","article_id":"2576882113","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576882113","pubTimestamp":1760936779,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IP Group plc announced new clinical data from Artios Pharma Limited regarding its novel DNA polymerase Theta  inhibitor, ART6043. The results from the Phase 1/2a clinical study  were presented at the European Society for Medical Oncology  Congress 2025. The study evaluated ART6043 both as a monotherapy and in combination with the PARP inhibitor olaparib in patients with advanced solid tumors, particularly those with mutations in DNA damage response pathways. ART6043 demonstrated an attractive tolerability profile, expected pharmacokinetic and pharmacodynamic activity, and promising clinical signals. The findings support the potential advancement of ART6043 into Phase 2 clinical development. Full abstracts will be published in the ESMO Congress 2025 Abstract Book, a supplement to the Annals of Oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPO.UK":"IP GROUP","BK5078":"资产管理与托管银行"},"translate_title":"Artios在ESMO 2025上公布了pol θ抑制剂ART6043有希望的1/2a期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPO.UK":0.9},"content_text":"Artios Unveils Promising Phase 1/2a Data for Polθ Inhibitor ART6043 at ESMO 2025\n    \n\n        IP Group plc announced new clinical data from Artios Pharma Limited regarding its novel DNA polymerase Theta (Polθ) inhibitor, ART6043. The results from the Phase 1/2a clinical study (NCT05898399) were presented at the European Society for Medical Oncology (ESMO) Congress 2025. The study evaluated ART6043 both as a monotherapy and in combination with the PARP inhibitor olaparib in patients with advanced solid tumors, particularly those with mutations in DNA damage response pathways. ART6043 demonstrated an attractive tolerability profile, expected pharmacokinetic and pharmacodynamic activity, and promising clinical signals. The findings support the potential advancement of ART6043 into Phase 2 clinical development. Full abstracts will be published in the ESMO Congress 2025 Abstract Book, a supplement to the Annals of Oncology.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576882113","isCrawlerRequest":true}